AbCellera Biologics Inc (OQ:ABCL)

Business Focus: Biotechnology & Medical Research

Nov 09, 2021 04:05 pm ET
AbCellera Reports Q3 2021 Business Results
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the third quarter of 2021. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
Nov 04, 2021 04:05 pm ET
AbCellera Announces Virtual Presentations at Investor Conferences in November
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following virtual investor conferences:
Nov 02, 2021 04:04 pm ET
Lilly to Supply 614,000 Additional Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab to the U.S. Government for the Treatment or Post-Exposure Prevention of COVID-19
AbCellera (Nasdaq: ABCL) today announced an additional purchase by the U.S. government from Eli Lilly and Company (Lilly) for bamlanivimab with etesevimab for administration together. This neutralizing antibody therapy is authorized for emergency use for the treatment of mild to moderate COVID-19 or for post-exposure prophylaxis of COVID-19 in certain ind
Oct 14, 2021 04:05 pm ET
AbCellera to Report Third Quarter 2021 Financial Results on November 9, 2021
AbCellera (Nasdaq: ABCL) will announce its third quarter 2021 financial results on Tuesday, November 9, 2021, and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
Sep 22, 2021 06:00 pm ET
AbCellera and Everest Medicines Announce Multi-Target Collaboration to Advance New Antibody Therapies
AbCellera (Nasdaq: ABCL) and Everest Medicines Limited (HKEX 1952.HK, “Everest”) announced t
Sep 21, 2021 01:55 pm ET
Lilly to Supply the EU and EEA with up to 220,000 Doses of AbCellera-Discovered Bamlanivimab Together with Etesevimab for the Treatment of Confirmed COVID-19
AbCellera (Nasdaq: ABCL) today announced the European Commission (EC) and Eli Lilly and Company (Lilly) have entered into a Joint Procurement Agreement to supply up to 220,000 doses of bamlanivimab together with etesevimab to treat confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at in
Sep 17, 2021 08:30 am ET
Thinking about buying stock in Corvus Pharmaceuticals, AbCellera Biologics, Rekor Systems, SmileDirectClub, or Arcus Biosciences?
NEW YORK, Sept. 17, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CRVS, ABCL, REKR, SDC, and RCUS.
Sep 16, 2021 04:15 pm ET
Emergency Use Authorization of AbCellera-Discovered Bamlanivimab Administered with Etesevimab Expanded by the FDA to Include Post-Exposure Prophylaxis for the Prevention of COVID-19
AbCellera (Nasdaq: ABCL) today announced the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg administered with etesevimab (LY-CoV016) 1400 mg to include post-exposure prophylaxis (PEP) to prevent SARS-CoV-2 infection or symptomatic COVID-19. The neutralizing antibodies, which we
Sep 15, 2021 09:00 am ET
AbCellera Announces Collaboration with Moderna to Discover Therapeutic Antibodies for mRNA Medicines
AbCellera (Nasdaq: ABCL) announced today that it entered into a multi-year, multi-target research collaboration and license agreement with Moderna to leverage AbCellera’s AI-powered technology to search and analyze natural immune responses to identify therapeutic antibodies against up to six targets selected by Moderna.
Sep 13, 2021 09:00 am ET
AbCellera Acquires TetraGenetics, Enhancing Capabilities to Generate Antibodies Against High-Value Targets
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has acquired TetraGenetics, Inc. (TetraGenetics), a biotechnology company with a proprietary platform for generating recombinant human ion channels and other transmembrane proteins, in an all-cash transaction that includes an upfront payment, the potential for payments based on the achievement of technical milestones, and additional development and commercial milestone payments related to successfully developed therapeutics.
Sep 10, 2021 04:17 pm ET
AbCellera to Present Virtually at the BofA Securities – Tech Solutions for Drug Discovery Conference
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the BofA Securities  – Tech Solutions for Drug Discovery Conference on Monday, September 20, 2021, at 9:00 a.m. Pacific Time.
Sep 07, 2021 08:30 am ET
Thinking about buying stock in Adaptimmune Therapeutics, Ziopharm Oncology, Uniqure NV, GlycoMimetics, or AbCellera Biologics?
NEW YORK, Sept. 7, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ADAP, ZIOP, QURE, GLYC, and ABCL.
Aug 12, 2021 04:05 pm ET
AbCellera Reports Q2 2021 Business Results
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the second quarter of 2021. All financial information in this press release is reported in U.S. dollars, unless otherwise indicated.
Aug 04, 2021 07:00 am ET
EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines
EQRx, a company committed to developing and delivering important new medicines at radically lower prices, and AbCellera (Nasdaq: ABC
Aug 04, 2021 07:00 am ET
EQRx and AbCellera Announce Collaboration to Accelerate the Advancement of New Innovative Medicines
EQRx, a company committed to developing and delivering important new medicines at radically lower prices, and AbCellera (Nasdaq: ABC
Aug 03, 2021 06:00 am ET
Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer
Tachyon Therapeutics, Inc. (Tachyon), a research and development focused biotechnology company, and AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced a collaboration to facilitate the discovery and development of a therapeutic antibody targeting LEFTY1, a member of the transforming growth factor β (TGF-β) superfamily and validated extracellular drug target expressed in advanced cancers. Under the terms of the agreement, AbCellera is eligible to receive milestone payments and royalties on products that are
Jul 22, 2021 04:05 pm ET
AbCellera to Report Second Quarter 2021 Financial Results on August 12, 2021
AbCellera (Nasdaq: ABCL) will announce its second quarter 2021 financial results on Thursday, August 12, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
Jul 13, 2021 09:00 am ET
AbCellera Appoints Neil Berkley as Chief Business Officer
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, announced today that Neil Berkley has been appointed as Chief Business Officer (CBO). Mr. Berkley’s role will include leading the strategy and continued growth of AbCellera’s partnership business, which currently includes a diverse po
Jun 22, 2021 09:00 am ET
AbCellera Continues Expansion and Strengthens Future Pandemic Preparedness with First-of- its-Kind GMP Manufacturing Facility for Therapeutic Antibodies in Canada
AbCellera (Nasdaq: ABCL) today announced it has secured a site in Vancouver for the construction of a Good Manufacturing Practices (GMP) manufacturing facility for the production of therapeutic antibodies, which will be the first of its kind in Canada. The 130,000-square-foot facility will expand AbCellera’s capabilities in bringing new antibody therapies to clinical trials, supporting Canada’s efforts to respond quickly and effectively to future pandemics and providing AbCellera’s partners with a full solution for accelerating their programs from a drug target to the submission of an Investig
Jun 10, 2021 05:11 pm ET
AbCellera Announces Secondary Private Sale of 11.9 Million Common Shares
AbCellera (Nasdaq: ABCL) today announced that certain entities owned and/or controlled, directly or indirectly, by Carl Hansen, Ph.D., Cofounder, Chief Executive Officer, and President of AbCellera, and other senior leaders (collectively, the “Selling Shareholders”), have entered into separate share purchase agreements with experienced institutional investors
May 14, 2021 08:48 pm ET
CORRECTING and REPLACING AbCellera Reports Q1 2021 Business Results
In the release dated May 13, 2021, the “Program starts, cumulative” figure for the period ended March 31, 2021 in both the Key Business Metrics table and the following paragraph should read 54 instead of 52. The resulting percent change from the prior period (“Change %) in the table should read 15% instead of 11%.
May 13, 2021 04:05 pm ET
AbCellera Reports Q1 2021 Business Results
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the first quarter of 2021.
May 11, 2021 04:05 pm ET
AbCellera to Present Virtually at Berenberg Conference on May 18, 2021
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present virtually at the Berenberg Conference USA 2021 on Tuesday, May 18, 2021 at 11:00 a.m. Pacific Time.
May 06, 2021 09:00 am ET
AbCellera Partners with Angios to Develop Therapeutics to Combat Blindness Caused by Diabetic Retinopathy
AbCellera (Nasdaq: ABCL) and Angios GmbH (Angios) announced today that they have entered into a multi-year, multi-target collaboration to facilitate the discovery of monoclonal and bispecific antibodies for vascular diseases of the eye. AbCellera will use its full stack, AI-powered antibody discovery platform to generate panels of antibodies for up to three Angios-selected targets to address diabetic retinopathy.
May 04, 2021 06:30 am ET
New AbCellera-Discovered Antibody that Neutralizes Viral Variants of COVID-19, LY-CoV1404, Enters Clinical Trials
AbCellera (Nasdaq: ABCL) today announced that a second antibody from its collaboration with Eli Lilly and Company (Lilly), LY-CoV1404, has entered
Apr 29, 2021 04:10 pm ET
AbCellera Breaks Ground on Global Headquarters in Vancouver and Expects to Hire Hundreds of Scientific and Tech Professionals
AbCellera (Nasdaq: ABCL), a technology company that has developed a centralized operating system for next-generation antibody discovery and development, today announced it has broken ground on an expanded global headquarters in its home city of Vancouver in anticipation of adding hundreds of employees to its current 250-person workforce over the next few years.
Apr 21, 2021 04:05 pm ET
AbCellera to Report First Quarter 2021 Financial Results on May 13, 2021
AbCellera (Nasdaq: ABCL) will announce its first-quarter 2021 financial results on Thursday, May 13, 2021 and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
Apr 14, 2021 04:05 pm ET
AbCellera and Empirico Announce Strategic Multi-Target Antibody Discovery Collaboration
AbCellera (Nasdaq: ABCL) and Empirico Inc. (“Empirico”) announced today that they have entered into a strateg
Apr 12, 2021 04:05 pm ET
AbCellera to Present Virtually at Upcoming Investor Conferences
AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the following virtual investor conferences:
Apr 05, 2021 02:00 pm ET
Published Peer-Reviewed Data Demonstrate Bamlanivimab’s High Potency Against SARS-CoV-2 and Support its Use as a Foundational Antibody Therapy to Treat and Prevent COVID-19
AbCellera (Nasdaq: ABCL) and collaborators today announced the publication of research in Science Translational Medicine characterizing the high potency of bamlanivimab (LY-CoV555) to neutralize SARS-CoV-2 by uniquely binding both the up and down confirmations of the spike receptor-b
Apr 01, 2021 09:00 am ET
AbCellera and Gilead Sciences Announce New Multi-Year, Multi-Target Antibody Discovery Collaboration
AbCellera (Nasdaq: ABCL) today announced agreements to expand its collaboration with Gilead Sciences, Inc. (Gilead) including a multi-year, multi-target antibody discovery collaboration and access to AbCellera’s humanized mouse technology, the Trianni Mouse®. Under the financial terms of the agreements, AbCellera will receive an upfront paym
Mar 29, 2021 04:05 pm ET
AbCellera Reports Full Year 2020 Business Results
AbCellera (NASDAQ: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced financial results for the full year 2020 with the following highlights.
Mar 10, 2021 11:21 am ET
AbCellera-Discovered Bamlanivimab Together with Etesevimab Reduced Hospitalizations and Prevented Death in Phase 3 Trial for Early COVID-19
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 700 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 1400 mg (LY-CoV16) together reduced COVID-19-related hospitalizations and deaths by 87% in high-risk patients recently diagnosed with COVID-19. These results mark the secon
Mar 05, 2021 03:30 pm ET
EMA Advises Use of AbCellera-Discovered Bamlanivimab, Alone or Together with Etesevimab, to Treat Confirmed COVID-19 Patients
AbCellera (Nasdaq: ABCL) today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific opinion for bamlanivimab alone and bamlanivimab administered together with etesevimab. The opinion advises bamlanivimab alone and bamlanivimab administered together with etesevimab can be used for the treatment of confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for COVID-19 and who are at high risk of progressing to severe COVID-19. The CHMP recommendation provides a harmonized,
Feb 17, 2021 04:05 pm ET
AbCellera to Present at the SVB Leerink Global Healthcare Conference
AbCellera (NASDAQ: ABCL) will present at the 10th Annual SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:20 p.m. Pacific Time.
Feb 11, 2021 04:05 pm ET
AbCellera Appoints Ester Falconer, Ph.D., as Chief Technology Officer
AbCellera (Nasdaq: ABCL) announced today that Ester Falconer, Ph.D., has been appointed as Chief Technology Officer (CTO), effective January 28, 2021.
Feb 09, 2021 08:26 pm ET
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Receives FDA Emergency Use Authorization for COVID-19
“The data show that bamlanivimab alone and bamlanivimab and etesevimab together are effective at reducing hospitalizations in high-risk COVID-19 patients, with consistent and similar efficacy across studies,” said Carl Hansen, Ph.D., CEO and President of AbCellera. “With this EUA for bamlanivimab and etesevimab together, there are more treatment options for patients at high risk for hospitalization and another layer of protection against the emergence of new viral variants.”
Feb 03, 2021 04:05 pm ET
AbCellera Announces Date of Fourth Quarter 2020 Financial Results Conference Call
AbCellera (Nasdaq: ABCL) will announce its fourth-quarter and full-year 2020 financial results on Monday, March 29, 2021 after the U.S. stock markets close and hold an earnings conference call at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) the same day.
Jan 27, 2021 07:22 am ET
AbCellera-Discovered Antibody, Bamlanivimab, to be Developed with VIR-7831 for the Treatment of COVID-19
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), will be evaluated together with VIR-7831, an antibody developed by Vir Biotechnology, Inc. and GlaxoSmithKline, as a potential COVID-19 therapy in low-risk patients with mild to moderate COVID-19
Jan 26, 2021 07:09 am ET
AbCellera-Discovered Antibody, Bamlanivimab, Administered with Etesevimab Reduced Risk of COVID-19 Hospitalizations and Death by 70%
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555) 2800 mg, a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), and etesevimab 2800 mg (LY-CoV16) together significantly reduced COVID-19 related hospitalizations and deaths (collectively, “events”) in more than 1,000 high-risk patients recently diagnosed with COVID-19.
Jan 21, 2021 08:27 am ET
AbCellera-Discovered Antibody Prevented COVID-19 in Nursing Homes and Reduced Risks by up to 80% for Residents
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody discovered by AbCellera and developed with Eli Lilly and Company (Lilly), significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities. Lilly’s Phase 3 BLAZE-2 COVID-19 prevention trial was conducted in partnership with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and the COVID-19 Prevention Network (CoVPN).
Jan 19, 2021 04:41 pm ET
AbCellera Granted U.S. Patent Covering its Trianni Mouse® Technology
AbCellera (Nasdaq: ABCL), a technology company with a centralized operating system for next-generation antibody discovery, today announced it has expanded its intellectual property (IP) portfolio to include its Trianni Mouse® technology. AbCellera uses the transgenic animal technology to generate fully human monoclonal antibodies for its drug di
Jan 05, 2021 08:30 am ET
2020 Canadian IPO mixed results - number (77) down, amount ($5.55B) up driven by PE-backed IPOs
TORONTO, Jan. 5, 2021 /CNW/ - While the US initial public offering (IPO) and special purpose acquisition corporation (SPAC) market experienced an unprecedent boom in 2020, Canadian IPO market continued to struggle with mixed results.
Dec 21, 2020 09:00 am ET
AbCellera-Discovered Neutralizing Antibody for COVID-19 Enters New Pragmatic Study in New Mexico
AbCellera (Nasdaq: ABCL) today announced that bamlanivimab (LY-CoV555), a human antibody developed through AbCellera’s collaboration with Eli Lilly and Company (Lilly), will be evaluated in a new pragmatic study in high-risk patients with COVID-19. Lilly’s trial, in collaboration with the state of New Mexico and major local institutions, will collect data on the effectiveness and safety of bamlanivimab in a real-world setting that includes a diverse population and spans both rural and urban environments. As part of this study, Lilly will employ its unique mobile research units used successfull
Dec 15, 2020 09:03 pm ET
AbCellera Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
AbCellera Biologics Inc. (“AbCellera”) (Nasdaq: ABCL), a technology company that aims to become the centralized operating system for next-generation antibody discovery, today announced the closing of its initial public offering of 27,772,500 common shares at a price to the public of $20.00 per share, which includes the exercise in full of the underwriters’ option to purchase 3,622,500 additional common shares. All of the common shares were offered by AbCellera. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were ap
Dec 10, 2020 10:47 pm ET
AbCellera Announces Pricing of Initial Public Offering
AbCellera Biologics Inc. (“AbCellera”), a technology company that aims to become the centralized operating system for next-generation antibody discovery, today announced the pricing of its initial public offering of 24,150,000 common shares at a price to the public of $20.00 per share. All of the common shares are being offered by AbCellera. In addition, AbCellera has granted the underwriters a 30-day option to purchase up to 3,622,500 additional common shares at the initial public offering price, less underwriting discounts and commissions. The shares are expected to begin trading on The Nasd

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.